Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.

In Model 2, restricting the analysis to patients turning negative 5–9 days after COVID-19 diagnosis, the effect of the two antivirals vanished, whereas the vaccination’s effect was reinforced for any dose number, particularly four (aHR = 5.55; 95% CI: 1.58; 19.45), although the estimates for the booster did not reach statistical significance ( Table 7 ). 3.

also in 111,027 other papers